maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary dis. e (COPD) including chronic bronchitis and emphysema. SYMBICORT 160/4.5 is the only approved do.

Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) reduces asthma exacerbations and symptoms versus fixed-dose regimens plus short-acting beta (2)-agonists (SABA) in double-blind trials. Information is lacking regarding its effectiveness versus conventional best practice (CBP).

2009年3月2日 · AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SYMBICORT (budesonide/formoterol fumarate dihydrate) 160/4.5 mcg for the twice daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

2016年7月28日 · Symbicort® Inhalation Aerosol Generic Name: Budesonide and formoterol fumarate dihydrate Sponsor: AstraZeneca Route of Administration: Inhalation

SYMBICORT pMDI was approved in July 2006 for the long-term maintenance treatment of asthma in patients 12 years of age and older (NDA 21-929). It was approved in February 2009 for the...

The product under discussion, Symbicort Inhalation Aerosol [Symbicort], is an HFA-propelled metered dose inhaler [MDI]. However, some products and formulations used prior to 2007 used

商品名:symbicort,活性成分:budesonide; formoterol fumarate dihydrate,申请号:021929,申请人:astrazeneca

2017年1月26日 · Symbicort (budesonide and formoterol) is a combination of a corticosteroid and a long-acting bronchodilator indicated for the long-term maintenance treatment of asthma and the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Symbicort is a combination inhaler used in asthma and chronic obstructive pulmonary disease (COPD) that contains budesonide and formoterol. In asthma, Symbicort can be used as fixed or adjustable dose maintenance therapy as well as for both …

Symbicort with the regimens 160/4.5 mg/inhalation has higher efficacy in reducing asthma symptom and improving its control compared with low doses of this drug and with Pulmicort. Keywords: Asthma symptom, symbicort, pulmicort